TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00682994

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interview
Description: Interview lasting about 5-10 minutes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire
Description: Questionnaires taking 20-30 minutes to complete.
Study: NCT03885999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fecobionics
Description: Fecobionics is a new device for studying defecation
Study: NCT01403259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin
Description: S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks
Study: NCT03991988

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Participants in this arm will take a matched placebo pill daily
Study: NCT04354246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose escalation: COM902 monotherapy.
Description: COM902 monotherapy administered IV every 3 weeks in sequential dose escalation doses in cohorts of subjects.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)
Description: Both study drugs will be evaluated at the RDFE for assessment of safety and tolerability. All study drugs will be administered IV every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort expansion: COM902 (RDFE) monotherapy.
Description: COM902 monotherapy (RDFE) in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort expansion: COM902 in combination with COM701 (both at the RDFE).
Description: COM902 in combination with COM701 (both at RDFE) in subjects with select tumor types who have exhausted standard treatment - HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.
Description: Triplet combination of COM902 + COM701 + Pembrolizumab administered IV every 3 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.
Description: Triplet combination of COM902 + COM701 + Pembrolizumab administered IV every 3 weeks.
Study: NCT03418493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3316531 - IV
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3316531 - IV
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3316531 - IV
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3316531 - SC
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - IV
Description: Administered IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - IV
Description: Administered IV.
Study: NCT00264030

Intervention type: DEVICE
Group type: OTHER
Intervention: Angioguard distal protection device
Description: PTCA with the Angioguard distal protection device.

Intervention type: OTHER
Group type: OTHER
Intervention: PTCA
Description: PTCA
Study: NCT04562857

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity interval training (MITT)
Description: interval exercises (intervention) on bicycle for patients with AF and OSA or AF with CSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity interval training (MITT)
Description: interval exercises (intervention) on bicycle for patients with AF and OSA or AF with CSA for 10 weeks, 3 times/week for duration of 30-45 min/ session.
Study: NCT02635009

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Three-Dimensional Conformal Radiation Therapy
Description: daily fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: daily fractions
Study: NCT02238756

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV8102
Description: Subjects will receive 2 intramuscular doses of CV8102 given 21 days apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabipur
Description: Subjects will receive 2 intramuscular doses of Rabipur given 21 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV8102 + Rabipur
Description: Subjects will receive 2 intramuscular doses of CV8102+Rabipur given 21 days apart
Study: NCT00396383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Participants were given a 240 µg/kg dose of plerixafor by subcutaneous injection in the morning followed by apheresis 6 hours later. Daily treatment with plerixafor followed by apheresis was administered for up to 4 consecutive days or until 4\*10\^6 CD34+ cells/kg body weight had been collected.
Study: NCT03825185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcervical Thymectomy
Description: Transcervical Thymectomy. All transcervical thymectomies were performed with an 8 cm transversal cervicotomy was performed approximately 2 cm above the sternal notch. Musculocutaneous flaps were developed up to the thyroid cartilage and the suprasternal notch. Strap muscles were split in the middle and retracted laterally. The upper horns of the thymus were exposed and were freed up to the level of the innominate vein. All tributary veins were suture ligated. A sternal retractor was then placed to retract the sternum upward until the patient was nearly lifted off the table. The rest of the Thymus was dissected, from the pericardium and the pleura. Care was specially taken to remove as much fatty tissue adjacent to the thymus as possible preserving the phrenic nerves.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transsternal Thymectomy
Description: Transsternal Thymectomy. A standard formal median sternotomy was carried out. The sternum was retracted laterally using an automatic retractor. All thymic tissue with the adjacent adipose tissue was removed starting with the inferior horns of the thymus. Thymic vessels were ligated and dissection was continued until the upper horns could be separated from the thyroid. A mediastinal tube was placed before closing the sternum and was kept in close suction for 2 to 3 days.
Study: NCT03077100

Intervention type: OTHER
Intervention: Laboratory identification of positive cultures
Description: Laboratory identification of positive cultures
Study: NCT02938234

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High caloric, high protein ONS
Study: NCT03662815

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNeo-Vac-P01
Description: Neoantigen peptides

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: immune adjuvant
Study: NCT02475759

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional perioperative prehabilitation program for two weeks
Description: nutritional intervention received two weeks before surgical intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional perioperative prehabilitation program for one week
Description: nutritional intervention received one weeks before surgical intervention
Study: NCT00895570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Description: During each day of the 7-day sleep restriction phase of the study modafinil was administered (200 mg tablet at 0600, and a second dose of 100 mg tablet at 1300).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: During each day of the 7-day sleep restriction phase of the study a sugar pill was administered.
Study: NCT03604575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Study: NCT02245919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Back on Track intervention
Description: A biopsychosocial primary care intervention based on multidisciplinary pain rehabilitation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
Study: NCT03828682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Extended Release Oral Tablet [Envarsus]
Description: Tacrolimus Extended Release Oral Tablet \[Envarsus\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil capsules or tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil capsules or tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic Acid Oral Product
Description: mycophenolic acid tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic Acid Oral Product
Description: mycophenolic acid tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Twice daily tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone taper

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone taper

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone taper

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone taper

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]
Description: Rabbit Anti-Human T-Lymphocyte Globulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]
Description: Rabbit Anti-Human T-Lymphocyte Globulin
Study: NCT02342600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: A kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma and advanced soft tissue sarcoma who have receive prior chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: A kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
Study: NCT01941537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILV-094
Description: IV infusion of ILV-094

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of a placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
Study: NCT04103034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT200
Description: BT200 is a PEGylated synthetic RNA oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT200
Description: BT200 is a PEGylated synthetic RNA oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT200
Description: BT200 is a PEGylated synthetic RNA oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT200
Description: BT200 is a PEGylated synthetic RNA oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT200
Description: BT200 is a PEGylated synthetic RNA oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT200
Description: BT200 is a PEGylated synthetic RNA oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT200
Description: BT200 is a PEGylated synthetic RNA oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT200
Description: BT200 is a PEGylated synthetic RNA oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT200
Description: BT200 is a PEGylated synthetic RNA oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT200
Description: BT200 is a PEGylated synthetic RNA oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT200
Description: BT200 is a PEGylated synthetic RNA oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT200
Description: BT200 is a PEGylated synthetic RNA oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT200
Description: BT200 is a PEGylated synthetic RNA oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT200
Description: BT200 is a PEGylated synthetic RNA oligonucleotide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BT200
Description: BT200 is a PEGylated synthetic RNA oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Sterile solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Desmopressin
Description: Sterile solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline for injection
Study: NCT02721017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural (ropivicaine, fentanyl)
Description: Epidural infusion was begun with with 0.1% ropivicaine and 2 mg/cc fentanyl.
Study: NCT00677573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostimon
Description: 450 IU for 4 days then adjusted
Study: NCT00596999

Intervention type: PROCEDURE
Intervention: UCB and HPDSC
Description: single dose of UCB followed by one unit of HPDSC
Study: NCT02479464

Intervention type: GENETIC
Group type: OTHER
Intervention: Genotyping results
Description: Genotyping results provided in Phase II
Study: NCT04544553

Intervention type: OTHER
Group type: OTHER
Intervention: SMS reminder
Description: The group receives reminder for the follow-up at 1 week and 2 days prior to their scheduled appointments.

Intervention type: OTHER
Group type: OTHER
Intervention: No SMS reminder
Description: The group did not receives any SMS regarding scheduled appoinments.
Study: NCT00639392

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a single dose of placebo administered by vein over about 15 minutes. Placebo is mostly water without Zoledronic Acid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Patients will receive a single dose of Zolendronic Acid. Zoledronic Acid is administered by vein over about 15 minutes.
Study: NCT01555710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifosfamide-tris
Description: 130 mg/m2/day 3 days every 21 days for a max of 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles.
Study: NCT02962206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound
Description: After the fracture reduction maneouver, the physician will assess residual dorsal angulation using point-of-care ultrasound. If deemed adequate, the physician will progress to immobilization. If the reduction is not adequate, the physician will attempt further reduction at their discretion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closed fracture reduction
Description: The distal radius fracture will be reduced with using a combination of local anesthetic, sedation, reduction maneouvers and immobiliazation at the discretion of the treating physician

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed fracture reduction
Description: The distal radius fracture will be reduced with using a combination of local anesthetic, sedation, reduction maneouvers and immobiliazation at the discretion of the treating physician
Study: NCT02577926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for the treatment of symptomatic myelofibrosis. The compound was shown to be superior to hydroxyurea in reducing splenomegaly and constitutional symptoms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT
Description: BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc).
Study: NCT01478607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QUTENZA
Description: A Qutenza (8% capsaicin) patch will be applied to identified painful areas for 30 minutes (Arm 1) or 60 minutes (Arm 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QUTENZA
Description: A Qutenza (8% capsaicin) patch will be applied to identified painful areas for 30 minutes (Arm 1) or 60 minutes (Arm 2).
Study: NCT03718195

Intervention type: OTHER
Group type: OTHER
Intervention: Pediatric Formula
Description: One week intake diary, one week tolerance diary, product intake
Study: NCT03930784

Intervention type: OTHER
Intervention: Nil intervention
Study: NCT03387501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors (PRGF-Endoret)
Description: Intrauterine administration of PRGF
Study: NCT00571025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APOE Disclosure
Description: Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease and told their own APOE genotype.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: APOE Disclosure
Description: Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease and told their own APOE genotype.
Study: NCT04217642

Intervention type: PROCEDURE
Intervention: Osteosynthesis
Description: The specific surgical technique -osteosynthesis, hemiarthroplasty, or total hip arthroplasty- will depend on the characteristics of the proximal femur fracture in each patient.
Study: NCT02510820

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synergi
Description: Multipurpose solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biotrue
Description: Multipurpose solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stenfilcon A
Description: daily disposable contact lenses for washout period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stenfilcon A
Description: daily disposable contact lenses for washout period
Study: NCT03013790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Patients will receive Melatonin at 2 different doses or a placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Patients will receive Melatonin at 2 different doses or a placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin
Description: Patients will receive Melatonin at 2 different doses or a placebo
Study: NCT01529294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Study: NCT00813436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin (also: syntocinon, pitocin)
Description: 24 IU for each subject (3 puffs in each nostril, 4 IU in each puff). each subject will receive a single administration, 40 minuets before task start time.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline liquid, intranasally administered
Study: NCT02860390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Denver Health Asthma Management Program
Description: text message (SMS) support including educational, motivational, and resource content.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Denver Health Asthma Management Program
Description: text message (SMS) support including educational, motivational, and resource content.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Denver Health Asthma Management Program
Description: text message (SMS) support including educational, motivational, and resource content.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Person of Support
Description: Subjects in the adolescent cohort will designate a support person (e.g. parent) to receive messages from the Denver Health Asthma Management Program
Study: NCT01864252

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischaemic preconditioning
Description: 3 cycles of 5 minutes to arm and legs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning
Description: 3 cycles of 5 minutes to arm and legs

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: IV Normal saline
Description: Normal saline IV started prior to knife to skin at a rate of 2-5 mls/h and stopped just after weaning off bypass.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Normal saline
Description: Normal saline IV started prior to knife to skin at a rate of 2-5 mls/h and stopped just after weaning off bypass.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Glyceryl trinitrate 2-5ml/h
Description: IV GTN given during surgery started prior to knife to skin and stopped after weaning off cardiopulmonary bypass.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Glyceryl trinitrate 2-5ml/h
Description: IV GTN given during surgery started prior to knife to skin and stopped after weaning off cardiopulmonary bypass.
Study: NCT02152098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute Early onset of rehabilitation
Description: Early onset of rehabilitation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute Delayed onset of rehabilitation
Description: Delayed onset of rehabilitation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chronic Exercise
Description: Exercise

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chronic Control
Description: Control
Study: NCT04283110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrthecl midazolam
Description: midazolm as as adjuvant in spinal anesthesia